论文部分内容阅读
目的探讨多巴丝肼片(美多芭)联合普拉克索治疗帕金森病的有效性及安全性。方法 100例帕金森病患者,按照随机抽签法分为治疗组与对照组,每组50例。治疗组应用美多芭联合普拉克索治疗,对照组单纯采取美多芭治疗。对比两组患者治疗效果以及不良反应情况。结果治疗组治疗总有效率为98.0%,高于对照组的80.0%,差异具有统计学意义(P<0.05)。治疗后,治疗组患者的平均副反应量表(TESS)评分(2.1±0.6)分低于对照组的(3.9±1.3)分,差异有统计学意义(P<0.05)。结论美多芭联合普拉克索治疗帕金森病的临床效果肯定,有效性、安全性均较高,值得借鉴。
Objective To investigate the efficacy and safety of doxepasone hydrochloride (pramipexole) combined with pramipexole in the treatment of Parkinson’s disease. Methods 100 patients with Parkinson’s disease were randomly divided into treatment group and control group according to randomized drawing, with 50 cases in each group. The treatment group was treated with metoprolol combined with pramipexole, while the control group was treated with metoprolol alone. Comparison of two groups of patients with treatment and adverse reactions. Results The total effective rate of the treatment group was 98.0%, which was higher than that of the control group (80.0%), the difference was statistically significant (P <0.05). After treatment, the average TESS score (2.1 ± 0.6) in the treatment group was significantly lower than that in the control group (3.9 ± 1.3) (P <0.05). Conclusion The combination of pramipexole and pramipexole in the treatment of Parkinson’s disease is clinically effective and safe, which is worth learning from.